| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.AHJ.2013.07.007 |
| P698 | PubMed publication ID | 24016497 |
| P50 | author | Steven P Sedlis | Q42328564 |
| John A. Spertus | Q59976170 | ||
| William E Boden | Q60503412 | ||
| Daniel S Berman | Q89697826 | ||
| P2093 | author name string | William S Weintraub | |
| Koon K Teo | |||
| Merril Knudtson | |||
| G B John Mancini | |||
| Eric R Bates | |||
| David J Maron | |||
| Bernard R Chaitman | |||
| Marcin Dada | |||
| Pamela M Hartigan | |||
| David C Booth | |||
| William J Kostuk | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ejection fraction | Q641303 |
| revascularization | Q7317735 | ||
| P304 | page(s) | 481-487 | |
| P577 | publication date | 2013-08-02 | |
| P1433 | published in | American Heart Journal | Q2227156 |
| P1476 | title | Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial | |
| P478 | volume | 166 |
| Q39129336 | Challenges with Evidence-Based Management of Stable Ischemic Heart Disease |
| Q48679114 | Coronary revascularization vs. medical therapy following coronary-computed tomographic angiography in patients with low-, intermediate- and high-risk coronary artery disease: results from the CONFIRM long-term registry |
| Q55315249 | Current Indications for Stenting: Symptoms or Survival CME. |
| Q40331861 | Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease |
| Q47151397 | Harmonizing the Paradigm With the Data in Stable Coronary Artery Disease: A Review and Viewpoint |
| Q37150897 | In-hospital measurement of left ventricular ejection fraction and one-year outcomes in acute coronary syndromes: results from the IMMEDIATE Trial |
| Q38552516 | Role of Fractional-Flow Reserve in Guiding Percutaneous Revascularization in Stable Coronary Artery Disease. |
| Q38679997 | The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease |
Search more.